| Sep 26 |
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
|
| Sep 26 |
Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
|
| Sep 26 |
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
|
| Sep 25 |
Amgen stock falls on lackluster drug data
|
| Sep 25 |
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
|
| Sep 25 |
Amgen stock slides 5% as analysts weigh in on drug study results
|
| Sep 25 |
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
|
| Sep 25 |
Amgen Stock Falls on Disappointing Drug Data
|
| Sep 25 |
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
|
| Sep 25 |
Amgen claims success for two immune drugs, but results underwhelm Wall Street
|
